MORI-BUILDING
24.5.2021 04:02:10 CEST | Business Wire | Press release
Mori Building Co., Ltd., Japan’s leading urban landscape developer, announced today that major redevelopments the company is undertaking in Tokyo have been precertified under the prestigious LEED (Leadership in Energy and Environmental Design) and WELL (WELL Building Standard) rating systems that respectively certify environmentally friendly and efficient green buildings and people’s wellbeing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210523005028/en/
The Toranomon-Azabudai Project and Toranomon Hills Area Project both received top Platinum-level LEED ND (Neighborhood Development, v.4) precertifications. The Toranomon-Azabudai and Toranomon Hills Area projects are respectively the first and second projects in Tokyo to be precertified Platinum in the ND category. LEED is the most widely used green-building rating system that evaluates and certifies buildings and cities worldwide for environmental performance in terms of water and energy efficiency, indoor environments and sustainable materials. LEED is managed by the U.S. Green Building Council (USGBC).
The A District of the Toranomon-Azabudai Project and the A-1 District of Toranomon Hills Station Tower (tentative name) received WELL (Core,v.2 Pilot) precertifications; the former is the world’s largest precertified property and the latter is Japan’s second largest precertified property. WELL is the world’s first performance-based system for measuring, certifying and monitoring features of the built environment that impact human health and wellbeing through air, water, nourishment, light, fitness, comfort and mind. WELL is also managed by the USGBC. Once completed, both projects are expected to obtain WELL Platinum certifications.
Mahesh Ramanujam, president and CEO of USGBC and also Green Business Certification Inc., which provides third-party credentialing and verification under the LEED, WELL and GRESB systems, said:
“Mori Building’s sustainability efforts and its LEED Platinum achievement are fine examples of how organizations can transform their communities by lowering carbon emissions, creating healthier environments and work towards a zero-carbon future.
Through
awarding advanced examples such as Mori building, we aspire to demonstrate how better buildings, better communities and better cities can help raise the living standard for all.”
Mori Building, based on its philosophy of “Create cities, nurture cities,” is committed to realizing a sustainable global society through the harmonious coexistence of cities and nature, low-carbon cities and truly enhanced health.
LEED ND Platinum Precertifications
The Toranomon-Azabudai Project was highly evaluated as a complex with diverse urban functions, a walkable urban center built with a central square, and also for its renewable-energy power supply. Toranomon Hills Station Tower was favorably assessed for its integration of public transportation, including the new subway station, and high-level energy efficiency.
In both projects, Mori Building’s emphasis on urban development in partnership with local landowners earned high marks in the ND category. Toranomon-Azabudai Project became Tokyo’s first project to earn a Platinum level in the ND category and Toranomon Hills Area Project quickly followed as the second such project. It is globally rare for complexes in urban business areas to receive Platinum-level precertification.
WELL Platinum Precertifications
The Toranomon-Azabudai Project’s A District and Toranomon Hills Station Tower (tentative name)’s A-1 District were highly evaluated as advanced urban redevelopments following the concept of each project, offering central squares with substantial greenery, indoor environments with excellent air quality through use of air conditioners equipped with high-performance filters, cafes serving healthful meals and layouts featuring central squares and elevated decks to promote exercise. Once completed, both projects are expected to obtain Platinum certifications.
The A District of the Toranomon-Azabudai Project is the world’s largest precertified property and the A-1 District of Toranomon Hills Station Tower (tentative name) is Japan’s second largest precertified property.
Reference: Toranomon-Azabudai Project
https://www.mori.co.jp/en/img/article/210524_2.pdf
About Toranomon-Azabudai Project
https://www.mori.co.jp/en/projects/toranomon_azabudai/
Toranomon-Azabudai Project Image Movie
https://www.youtube.com/watch?v=5akVE7tWOto&feature=emb_logo
Reference: Toranomon Hills Area project
https://www.mori.co.jp/en/img/article/210524_3.pdf
About Toranomon Hills Area project
https://www.mori.co.jp/en/projects/toranomonhills_area/
Press releases:
https://www.mori.co.jp/en/img/article/190822.pdf
https://www.mori.co.jp/en/img/article/200610_1.pdf
https://www.mori.co.jp/en/img/article/210218_1.pdf
About Mori Building
Mori Building is an innovative urban developer based in Tokyo. The company is committed to maximizing the magnetic power of cities by creating and nurturing safe, sustainable and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure and residence. The concept is applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management and consultation. Please visit www.mori.co.jp/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20210523005028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom